Table 4.
Correlation of EPAS1 mRNA expression with clinicopathological features of patients with esophageal squamous cell carcinoma.
| Features | Number | High | Low | No change | P-value |
|---|---|---|---|---|---|
| Total patients | 80 | 43 (53.7%) | 16 (20.0%) | 21 (26.3%) | – |
| Sex | |||||
| Male | 67 (83.8%) | 39 (58.2%) | 13 (19.4%) | 15 (22.4%) | 0.14 |
| Female | 13 (16.2%) | 4 (30.8%) | 3 (23.1%) | 6 (46.1%) | |
| Age | |||||
| ≤60 | 54 (67.5%) | 31 (57.4%) | 10 (18.5%) | 13 (24.1%) | 0.63 |
| >60 | 26 (32.5%) | 12 (46.2%) | 6 (23.1%) | 8 (30.7%) | |
| Site | |||||
| Upper or middle | 53 (66.3%) | 26 (49.1%) | 12 (22.6%) | 15 (28.3%) | 0.48 |
| Lower | 27 (33.7%) | 17 (63.0 %) | 4 (14.8%) | 6 (22.2%) | |
| Size (cm) | |||||
| ≤6 | 31 (38.7%) | 13 (41.9%) | 7 (22.6%) | 11 (35.5%) | 0.21 |
| >6 | 49 (61.3%) | 30 (61.2%) | 9 (18.4%) | 10 (20.4%) | |
| Differentiation | |||||
| Well | 24 (30.0%) | 15 (62.5%) | 4 (16.7%) | 5 (20.8%) | 0.75 |
| Moderate | 39 (48.8%) | 21 (53.8%) | 8 (20.5%) | 10 (25.7%) | |
| Poor | 17 (21.2%) | 7 (41.2%) | 4 (23.5%) | 6 (35.3%) | |
| T-stages | |||||
| I & II | 6 (7.5%) | 2 (33.3%) | 1 (16.7%) | 3 (50.0%) | 0.38 |
| III & IV | 74 (92.5%) | 41 (55.4%) | 15 (20.3%) | 18 (24.3%) | |
| Lymph-node metastasis | |||||
| Presence | 60 (75.0%) | 34 (56.6%) | 13 (21.7%) | 13 (21.7%) | 0.26 |
| Absence | 20 (25.0%) | 9 (45.0%) | 3 (15.0%) | 8 (40.0%) | |
| Distant metastasis | |||||
| Yes | 5 (6.3%) | 2 (40.0%) | 1 (20.0%) | 2 (40.0%) | 0.75 |
| No | 75 (93.7%) | 41 (54.7%) | 15 (20.0%) | 19 (25.3%) | |
| Stage | |||||
| I & II | 22 (27.5%) | 11 (50.0%) | 3 (13.6%) | 8 (36.4%) | 0.39 |
| III & IV | 58 (72.5%) | 32 (55.2%) | 13 (22.4%) | 13 (22.4%) | |